Semaglutide Plus Targeted Diet May Be the Future of Sustainable Obesity Treatment

Obesity now affects over 890 million adults worldwide, and its management increasingly requires pharmacological intervention alongside lifestyle change. Semaglutide, a once-weekly GLP-1 receptor agonist approved for chronic weight management at 2.4 mg subcutaneously, has demonstrated up to ~15–17% body weight reduction in the STEP phase 3 clinical trial programme—superior to prior anti-obesity medications. Yet the authors argue that pharmacotherapy alone is insufficient for durable results, and that structured nutritional strategies are essential co-interventions.

The review centers on two dietary frameworks. The Mediterranean diet—rich in olive oil, vegetables, legumes, whole grains, lean proteins, and anti-inflammatory polyphenols—is presented as well-suited for individuals with uncomplicated obesity. Its balanced macronutrient profile supports gradual, sustainable weight loss, mitigates low-grade inflammation, and is associated with favorable effects on the gut microbiome. Critically, its emphasis on fiber-rich, easily digestible foods may reduce the nausea, vomiting, and gastroparesis-like symptoms commonly reported with GLP-1RA therapy.

Very-low-energy ketogenic therapy (VLEKT), typically delivering fewer than 800 kcal/day with very low carbohydrates and high protein, is positioned for patients with significant metabolic comorbidities such as type 2 diabetes, metabolic-associated fatty liver disease, or severe dyslipidemia. Nutritional ketosis induced by VLEKT rapidly reduces fat mass and improves glycemic control, and the high protein content may synergize with semaglutide's anorectic effects to preserve lean body mass—a critical goal given that GLP-1RA-induced weight loss includes a meaningful proportion of muscle mass.

Both dietary strategies are evaluated against the key metric of body composition rather than weight alone. The authors stress that loss of lean body mass reduces resting metabolic rate, increases rebound weight gain risk, and diminishes functional capacity—making lean mass preservation a clinical priority equal to fat loss. They also highlight the role of the gut microbiome, noting that both the MD and semaglutide independently shift microbial composition toward favorable profiles, and that combined use may amplify these effects.

The review draws on the STEP trial series (STEP 1–10), which enrolled over 25,000 individuals and demonstrated semaglutide's efficacy across diverse populations including those with cardiovascular disease, sleep apnea, and adolescents. The authors acknowledge that direct head-to-head trials of semaglutide combined with specific dietary interventions remain scarce, and that most evidence supporting the integrated approach is mechanistic or inferential rather than derived from prospective randomized studies. They call for future trials explicitly testing semaglutide plus MD or VLEKT protocols to generate the evidence base this clinical strategy currently lacks.